EUVIMEDEUVIMED entdecken
Crossref

Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study

Zhaozhou Ren, Long Zhou

Inflammopharmacology · 2024

DOI: 10.1007/s10787-024-01441-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Zhaozhou Ren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedics, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, 110004, Liaoning Provinc…. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Osteoporosis. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypercholesterolemia and the related inflammatory response promote the development of osteoporosis, but whether targeted interventions are protective against this bone metabolic disease remains unknown. The aim of this study was to investigate the association between the use of statins (one well-recognized cholesterol-lowering drug with anti-inflammatory properties) and the risk of osteoporosis using a drug-targeted Mendelian randomization (MR) approach. METHODS: Instrumental variables predicting three cholesterol-lowering target genes (including HGMCR) and the cholesterol effectors mediated by these genes (i.e., total cholesterol, LDL cholesterol, and non-HDL cholesterol) were extracted from expression quantitative trait loci and genome-wide association studies. Inverse variance-weighted (IVW), summary data-based MR (SMR), multivariate MR, and colocalization analysis were used to determine the association of the interventions represented by these instrumental variables with heel bone mineral density (one diagnostic indicator of osteoporosis). RESULTS: The IVW reported that increased levels of HGMCR-mediated total cholesterol, LDL cholesterol, and non-HDL cholesterol were associated with the decreased level of heel bone mineral density (P = 4.086e-10, P = 1.487e-09, P = 1.967e-09). The colocalization analysis supported the relationship between HGMCR-mediated non-HDL cholesterol and heel bone mineral density. The SMR reported that higher expression of HGMCR was associated with the decreased level of this osteoporosis indicator (P = 0.036). The multivariate MR further confirmed the role of HGMCR in the correlation between cholesterol traits and heel bone mineral density, and also reported that estrogen played a mediating role in the above correlations. CONCLUSION: These evidence supported a protective effect of HMGCR-mediated non-HDL cholesterol reduction or statin use against osteoporosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsOsteoporosisHumansCholesterol, LDLGenome-Wide Association StudyMendelian Randomization AnalysisPolymorphism, Single Nucleotide

Stichwörter der Autor:innen

Drug targetHMG-CoA reductase inhibitorMendelian randomizationOsteoporosisStatins

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsCholesterol, LDL

Autor:innen und Institutionen

  • Department of Orthopedics, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China.
  • Department of Orthopedics, Shengjing Hospital of China Medical University, No. 36, Sanhao Street, Heping District, Shenyang, 110004, Liaoning Province, China. zhoulong34676@outlook.com.

Zitieren

APA

Ren, Z., & Zhou, L. (2024). Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01441-y

Vancouver

Ren Z, Zhou L. Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01441-y

BibTeX
@article{Ren2024,
  author = {Ren, Zhaozhou and Zhou, Long},
  title = {Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study},
  journal = {Inflammopharmacology},
  year = {2024},
  doi = {10.1007/s10787-024-01441-y}
}
Kostenlos starten →